Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Aug 23, 2022 8:04pm
154 Views
Post# 34915780

RE:Share Buybacks & Use of Cash

RE:Share Buybacks & Use of Cash
longrun86 wrote: I will start out by saying that this post contains "speculation" on my part.

An interesting point was made with the release of the Q2 results. Knight had made no further purchases under the NCIB. While the share price had appreciated somewhat, I don't think that it moved too far out of "value" territory.

Given the comments made by Management and the strategic use of capital, I believe that Management has identified better opportunities for the deployment of the current cash balance through both organic and in-organic opportunities. Time will reveal if this is in fact true.

The other potential view is that they view the "investment & loan" portfolio as requiring a bit more time to play out and reach maturity where they can realize the value and convert to cash.

I look forward to seeing Knight grow and make strategic investments in the coming quarters.

LR



True Longrun.
During the conference call, I think Samira also indicated that she was interested in beefing up assets for Canada and Mexico - seemed like that was her priority right now.

I could see GUD focus cash spend on acquisitions - if they are seeing opportunities.  Makes sense.
<< Previous
Bullboard Posts
Next >>